fluorouracil has been researched along with Cystadenocarcinoma, Serous in 6 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Cystadenocarcinoma, Serous: A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since the prognosis of recurrent ovarian cancer patients is still poor, we need to establish a useful treatment strategy to achieve their long-term survival." | 2.73 | Weekly paclitaxel/5-fluorouracil followed by platinum retreatment for patients with recurrent ovarian cancer: a single institution experience. ( Ebina, Y; Hosaka, M; Mitamura, T; Moriwaki, M; Ohba, Y; Sakuragi, N; Takeda, M; Todo, Y; Watari, H, 2008) |
| " After rAd-p53 treatment, one of the three relapsed ovarian cancers achieved complete remission(CR), one achieved partial remission (PR), and one was stable disease (SD); the treatment-naive patient was operated after rAd-p53 combined with neoadjuvant chemotherapy and achieved pathological CR." | 1.56 | Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer. ( Li, X; Qu, H; Xia, Y, 2020) |
| "A 59-year-old woman with advanced ovarian cancer complained of massive refractory ascites after 2 years' history of chemotherapy." | 1.32 | [A patient with stage IIIc ovarian cancer with massive ascites who was chemotherapy resistant showed complete response with intraperitoneal hyperthermic chemoperfusion]. ( Fujimoto, S; Kobayashi, K; Mutou, T; Ogasawara, T; Ohtsuka, Y; Takahashi, M; Toyosawa, T, 2003) |
| "pDOR-erbB-neo was introduced into human ovarian cancer cell line SKOV3 by lipofectin." | 1.29 | [Effect of antisense c-erbB2 on biologic behaviour and chemotherapeutic drug sensitivity in human ovarian cancer cells]. ( Jiang, K; Wu, A; Wu, L, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Qu, H | 1 |
| Xia, Y | 1 |
| Li, X | 1 |
| Watari, H | 1 |
| Hosaka, M | 1 |
| Mitamura, T | 1 |
| Moriwaki, M | 1 |
| Ohba, Y | 1 |
| Todo, Y | 1 |
| Takeda, M | 1 |
| Ebina, Y | 1 |
| Sakuragi, N | 1 |
| Marverti, G | 1 |
| Ligabue, A | 1 |
| Paglietti, G | 1 |
| Corona, P | 1 |
| Piras, S | 1 |
| Vitale, G | 1 |
| Guerrieri, D | 1 |
| Luciani, R | 1 |
| Costi, MP | 1 |
| Frassineti, C | 1 |
| Moruzzi, MS | 1 |
| Peled, Y | 1 |
| Levavi, H | 1 |
| Krissi, H | 1 |
| Weill, Y | 1 |
| Sabah, G | 1 |
| Eitan, R | 1 |
| Kobayashi, K | 1 |
| Fujimoto, S | 1 |
| Takahashi, M | 1 |
| Mutou, T | 1 |
| Toyosawa, T | 1 |
| Ohtsuka, Y | 1 |
| Ogasawara, T | 1 |
| Wu, L | 1 |
| Wu, A | 1 |
| Jiang, K | 1 |
1 trial available for fluorouracil and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
Weekly paclitaxel/5-fluorouracil followed by platinum retreatment for patients with recurrent ovarian cancer: a single institution experience.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phyt | 2008 |
5 other studies available for fluorouracil and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer.
Topics: Adenoviridae; Aged; Bleomycin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Fatal Outcome; | 2020 |
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neopla | 2009 |
The use of Fluorouracil (5-FU) and leucovorin in women with heavily pretreated advanced ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary | 2013 |
[A patient with stage IIIc ovarian cancer with massive ascites who was chemotherapy resistant showed complete response with intraperitoneal hyperthermic chemoperfusion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplatin; Cystadenocarcinoma, Serous | 2003 |
[Effect of antisense c-erbB2 on biologic behaviour and chemotherapeutic drug sensitivity in human ovarian cancer cells].
Topics: Antineoplastic Agents; Cisplatin; Cystadenocarcinoma, Serous; DNA, Antisense; DNA, Complementary; Dr | 1996 |